Although the efficacy of EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) for EGFR mutation‐positive lung adenocarcinoma has been demonstrated, their effectiveness for EGFR‐mutated squamous cell carcinoma remains unclear. Here, EGFR is linked to squamous cell carcinoma.